Prof. Alain-Li Wan Po

Professor Alain Li-Wan-Po has written several books including, Non-Prescription Drugs, Dictionary of Evidence-Based Medicine, and Statistics for Pharmacists. He is a regular reviewer of major medical and pharmaceutical journals.

Alain Li-Wan-Po has served as a member of the UK Committee on Safety of Medicines and as pharmacogenomics lead at the UK National Genetics and Genomics Education Centre for several years, until its merger with Health Education England. He has acted as consultant and received research funding from numerous pharmaceutical companies including, Astra Zenecca, Bayer, Bristol-Myers Squibb, Glaxo-Smith Kline, Janssen Pharmaceuticals, Novartis, and Roche.

He has held the chair of Pharmaceutics at the Queen¡¯s University of Belfast, and the chair of Clinical Pharmaceutics at the University of Nottingham and the University of Aston, in the United Kingdom. He has been external examiner at numerous universities including Robert Gordon University, The University of Bristol, The University of Cardiff, The Chinese University of Hong-Kong, The University of Geneva, The University of Liverpool, The University of London, The University of Malaya, the University of Manchester, The University of Reading, The University of Singapore, The University of Strathclyde, The University of Tasmania, and The University of Utrecht, within departments of pharmacy, nutrition, and medicine.

In addition to his training in drug development and therapy, Professor Li-Wan-Po also holds degrees in applied mathematics and statistics, and in economics and mathematical sciences.

He has written over 100 papers in scientific and medical journals and is a fellow of the Royal Pharmaceutical Society, and the Royal Statistical Society. He has also held the fellowship of the Royal Society of Chemistry and the Pharmaceutical Society of Northern Ireland. His current research interests focus on genomic and translational medicine.

His next book, Genomic Medicine from A to Z: An Introduction to the Vocabulary and Main Concepts, and a shorter version entitled, Genomic Medicine: Keynotes and concepts will be published later this year.